ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. lowered its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 34.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 98,489 shares of the specialty pharmaceutical company’s stock after selling 52,316 shares during the period. Principal Financial Group Inc.’s holdings in ANI Pharmaceuticals were worth $9,022,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Assenagon Asset Management S.A. increased its stake in ANI Pharmaceuticals by 259.4% during the third quarter. Assenagon Asset Management S.A. now owns 46,328 shares of the specialty pharmaceutical company’s stock worth $4,244,000 after acquiring an additional 33,438 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in shares of ANI Pharmaceuticals during the 3rd quarter worth $1,597,000. Decker Retirement Planning Inc. increased its position in shares of ANI Pharmaceuticals by 76,862.5% during the 3rd quarter. Decker Retirement Planning Inc. now owns 36,942 shares of the specialty pharmaceutical company’s stock worth $3,384,000 after purchasing an additional 36,894 shares during the last quarter. Intech Investment Management LLC raised its holdings in ANI Pharmaceuticals by 134.7% in the 2nd quarter. Intech Investment Management LLC now owns 26,917 shares of the specialty pharmaceutical company’s stock valued at $1,756,000 after buying an additional 15,447 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in ANI Pharmaceuticals in the second quarter valued at about $2,137,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Guggenheim lifted their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Finally, Barclays assumed coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They set an “overweight” rating and a $100.00 target price on the stock. Six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $103.43.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,622 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $82.40, for a total value of $133,652.80. Following the completion of the transaction, the senior vice president owned 58,564 shares in the company, valued at approximately $4,825,673.60. This trade represents a 2.69% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Renee P. Tannenbaum sold 1,800 shares of the business’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $81.15, for a total value of $146,070.00. Following the transaction, the director directly owned 25,157 shares of the company’s stock, valued at approximately $2,041,490.55. This represents a 6.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 4,322 shares of company stock valued at $354,816 in the last quarter. Corporate insiders own 11.10% of the company’s stock.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $76.70 on Friday. ANI Pharmaceuticals, Inc. has a 52 week low of $54.10 and a 52 week high of $99.50. The company has a fifty day simple moving average of $81.26 and a two-hundred day simple moving average of $85.77. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. The company has a market cap of $1.72 billion, a price-to-earnings ratio of 47.06 and a beta of 0.50.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.